Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Melanoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 335 (final count)
- Started
- Jul 1, 2020
- Main results expected
- May 18, 2026
- Fully finished
- May 18, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of participants who experience a dose-limiting toxicity (DLT): Safety lead-in phase
Measured over: Up to ~3 weeks
Percentage of participants who experience an adverse event (AE): Safety lead-in
Measured over: Up to ~3 weeks
Percentage of participants who discontinue study treatment due to an AE: Safety lead-in
Measured over: Up to ~3 weeks
Percentage of participants who experience an adverse event (AE)
Measured over: Up to ~28 months
Percentage of participants who discontinue study treatment due to an AE
Measured over: Up to ~24 months
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Measured over: Up to ~30 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04305054 · record last updated 2026-05-28 · checked 2026-11-09 15:47 UTC